Dec 2 (Reuters) - GSK PLC
* JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER
* GSK: JEMPERLI (DOSTARLIMAB) RUBY PHASE III TRIAL MET ITS PRIMARY ENDPOINT
* RESULTS SHOWED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN INVESTIGATOR-ASSESSED PROGRESSION-FREE SURVIVAL
* REGULATORY SUBMISSIONS BASED ON TRIAL RESULTS ARE PLANNED FOR FIRST HALF OF 2023 Source text for Eikon: